Alan Fuhrman was appointed to our board of directors in March 2020.
Alan has served as Chief Financial Officer of Amplyx Pharmaceuticals since December 2017.
He is a member of the board of directors for SpringWorks Therapeutics as well as the board of directors of Checkmate Pharmaceuticals.
Alan previously served as CFO of Mirna Therapeutics, a clinical-stage microRNA company that merged with Synlogic in August 2017 and at Ambit Biosciences, where he helped lead the company through its initial public offering and oversaw financial, investor and administrative operations until its sale to Daiichi Sankyo in 2014.
He brings over 20 years of executive financial experience in biotechnology, medical devices, technology and services. He has experience in a wide variety of both public and private company financial transactions.
Alan earned a BS in Business Administration, Accounting from Montana State University-Bozeman.